Combination Therapy Benefits Fabry Disease Patients
Combining an ACE inhibitor (ACEI) and angiotensin-receptor blocker (ARB) with enzyme replacement therapy using agalsidase-beta (Fabrazyme, Genzyme) may help stop progressive loss of kidney function in patients with severe kidney involvement due to Fabry disease, researchers report.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.